Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
What should you ask your plan before starting treatment
Any reference to biological activity or potential effects is based solely on preclinical or invitro findings and should not be interpreted as validated clinical outcomes
Ruxolitinib is particularly associated with the development of skin cancer, as 17.1% of patients on the therapy developed basal cell carcinoma or squamous cell carcinoma compared with 2.7% of patients on alternate available therapy for myelofibrosis (Figure 4)
Only inject into your upper arms with the help of someone else
US$ 20.29
US$ 26.18
US$ 20.71
US$ 24.05
US$ 28.11
US$ 24.74
US$ 22.42
